{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:50:07Z","timestamp":1790005807363,"version":"4.0.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interleukin (IL)-11 is a cytokine with thrombopoietic activity that has been shown to increase plasma von Willebrand factor (vWf) in preliminary clinical studies. This led to further evaluation of the effect of recombinant human (rh)IL-11 on vWf and factor VIII (FVIII) secretion. In vitro, rhIL-11 did not increase vWf production by cultured endothelial cells, which suggests an indirect mechanism. Also, in vivo, plasma vWf was not elevated in mice shortly after a single intravenous (IV) bolus injection of 250 or 1000 \u03bcg\/kg rhIL-11. The effect of continuous exposure to rhIL-11 was accessed by treating wild type mice for 7 consecutive days with subcutaneous 250 \u03bcg\/kg\/d rhIL-11. Platelet counts increased by 25% and 40% after 4 and 7 days, respectively. Plasma vWf and FVIII levels increased 2-fold after 4 and 7 days. Surprisingly, no effect of rhIL-11 on vWf or FVIII messenger RNA was observed, which suggests that the regulation by rhIL-11 occurs after transcription. No increase in soluble P-selectin was observed after rhIL-11 treatment, indicating that platelet activation is not the source of elevated vWf. Similarly to wild type mice, vWf heterozygous mice responded to rhIL-11 treatment by a significant increase in platelet counts and vWf and FVIII levels. Importantly, in vWf-deficient mice, rhIL-11 also induced a significant increase in FVIII independent of vWf and was able to reduce skin bleeding time. These results suggest that a clinical evaluation of the effects of rhIL-11\u2013induced vWf\/FVIII elevation in maintaining hemostasis in mild hemophilia A or von Willebrand disease would be worthwhile.<\/jats:p>","DOI":"10.1182\/blood.v97.2.465","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models"],"prefix":"10.1182","volume":"97","author":[{"given":"Ce\u0301cile V.","family":"Denis","sequence":"first","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyubum","family":"Kwack","sequence":"additional","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Saffaripour","sequence":"additional","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Maganti","sequence":"additional","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Andre\u0301","sequence":"additional","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Schaub","sequence":"additional","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa D.","family":"Wagner","sequence":"additional","affiliation":[{"name":"From The Center for Blood Research and the Department of Pathology, Harvard Medical School, Boston, MA, and Wyeth\/Genetics Institute, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020012418391154500_B1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/279636a0","article-title":"Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to the subendothelium.","volume":"279","author":"Sakariassen","year":"1979","journal-title":"Nature."},{"key":"2020012418391154500_B2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood.V65.4.823.823","article-title":"Factor VIII\/von Willebrand factor in subendothelium mediates platelet adhesion.","volume":"65","author":"Turitto","year":"1985","journal-title":"Blood."},{"key":"2020012418391154500_B3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1172\/JCI108788","article-title":"Stabilization of factor VIII in plasma by the von Willebrand factor: studies on post-transfusion and dissociated factor VIII and in patients with von Willebrand's diseases.","volume":"60","author":"Weiss","year":"1977","journal-title":"J Clin Invest."},{"key":"2020012418391154500_B4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1172\/JCI119195","article-title":"von Willebrand factor.","volume":"99","author":"Ruggeri","year":"1997","journal-title":"J Clin Invest."},{"key":"2020012418391154500_B5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2007-994004","article-title":"Therapy of von Willebrand disease.","volume":"19","author":"Scott","year":"1993","journal-title":"Semin Thromb and Hemostasis."},{"key":"2020012418391154500_B6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0308-2261(21)00484-7","article-title":"Von Willebrand disease.","volume":"14","author":"Holmberg","year":"1985","journal-title":"Clin Hematol."},{"key":"2020012418391154500_B7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand's disease.","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood."},{"key":"2020012418391154500_B8","first-page":"377","article-title":"Prevalence of von Willebrand's disease among US adults.","volume":"70","author":"Miller","year":"1987","journal-title":"Blood."},{"key":"2020012418391154500_B9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1046\/j.1365-2516.1998.440654.x","article-title":"Diagnosis of von Willebrand disease.","volume":"4","author":"Federici","year":"1998","journal-title":"Haemophilia."},{"key":"2020012418391154500_B10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2516.1998.440665.x","article-title":"Females with von Willebrand disease: 72 years as the silent majority.","volume":"4","author":"Kouides","year":"1998","journal-title":"Haemophilia."},{"key":"2020012418391154500_B11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1055\/s-0038-1651576","article-title":"Von Willebrand disease: a database of point mutations, insertions and deletions.","volume":"69","author":"Ginsburg","year":"1993","journal-title":"Thromb Haemost."},{"key":"2020012418391154500_B12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease.","volume":"71","author":"Sadler","year":"1994","journal-title":"Thromb Haemost."},{"key":"2020012418391154500_B13","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood."},{"key":"2020012418391154500_B14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2516.1998.440661.x","article-title":"Treatment of von Willebrand disease.","volume":"4","author":"Mannucci","year":"1998","journal-title":"Haemophilia."},{"key":"2020012418391154500_B15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1055\/s-0038-1657590","article-title":"New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates.","volume":"78","author":"Menache","year":"1997","journal-title":"Thromb Haemost."},{"key":"2020012418391154500_B16","first-page":"3607","article-title":"A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.","volume":"87","author":"Tepler","year":"1996","journal-title":"Blood."},{"key":"2020012418391154500_B17","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","article-title":"A phase I trial of recombinant interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood."},{"key":"2020012418391154500_B18","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.1997.15.11.3368","article-title":"Randomized placebo controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.","volume":"15","author":"Issacs","year":"1997","journal-title":"J Clin Oncol."},{"key":"2020012418391154500_B19","first-page":"1088a","article-title":"Recombinant human interleukin eleven (Neumega rhIL-11 growth factor) increases plasma von Willebrand factor and fibrinogen concentrations in normal human subjects [abstract].","volume":"84","author":"Kaye","year":"1994","journal-title":"Blood."},{"key":"2020012418391154500_B20","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1073\/pnas.95.16.9524","article-title":"A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.","volume":"95","author":"Denis","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020012418391154500_B21","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/sj.leu.2401514","article-title":"Hematopoietic, immunomodulatory and epithelial effects of interleukin-11.","volume":"13","author":"Schwertschlag","year":"1999","journal-title":"Leukemia."},{"key":"2020012418391154500_B22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/stem.5530130503","article-title":"Preclinical biology of interleukin-11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity.","volume":"13","author":"Goldman","year":"1995","journal-title":"Stem Cells."},{"key":"2020012418391154500_B23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-1759(97)00188-9","article-title":"Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood.","volume":"210","author":"Kruse","year":"1997","journal-title":"J Immunol Methods."},{"key":"2020012418391154500_B24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.6.10.986","article-title":"Real time quantitative PCR.","volume":"6","author":"Heid","year":"1996","journal-title":"Genome Res."},{"key":"2020012418391154500_B25","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1172\/JCI6910","article-title":"Interleukin-ll therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions.","volume":"10","author":"Trepicchio","year":"1999","journal-title":"J Clin Invest."},{"key":"2020012418391154500_B26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1083\/jcb.143.4.1129","article-title":"Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses.","volume":"143","author":"Hartwell","year":"1998","journal-title":"J Cell Biol."},{"key":"2020012418391154500_B27","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1083\/jcb.99.6.2123","article-title":"Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.","volume":"99","author":"Wagner","year":"1984","journal-title":"J Cell Biol."},{"key":"2020012418391154500_B28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(86)90735-X","article-title":"Inducible secretion of large biologically potent von Willebrand factor multimers.","volume":"46","author":"Sporn","year":"1986","journal-title":"Cell."},{"key":"2020012418391154500_B29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1055\/s-0038-1656116","article-title":"The origin of P-selectin as a circulating plasma protein.","volume":"77","author":"Fijnheer","year":"1997","journal-title":"Thromb Haemost."},{"key":"2020012418391154500_B30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.V74.4.1241.1241","article-title":"Interleukin 6 is a potent thrombopoietic factor in vivo in mice.","volume":"74","author":"Ishibashi","year":"1989","journal-title":"Blood."},{"key":"2020012418391154500_B31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/369568a0","article-title":"Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin.","volume":"369","author":"Kaushansky","year":"1994","journal-title":"Nature."},{"key":"2020012418391154500_B32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcp.1041530210","article-title":"Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro.","volume":"153","author":"Burstein","year":"1992","journal-title":"J Cell Physiol."},{"key":"2020012418391154500_B33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1963.tb05457.x","article-title":"Transfusion studies in von Willebrand's disease: effect on bleeding time and FVIII.","volume":"9","author":"Cornu","year":"1963","journal-title":"Br J Haematol."},{"key":"2020012418391154500_B34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood.V30.3.375.375","article-title":"Correction of the hemostatic defects in von Willebrand's disease.","volume":"30","author":"Perkins","year":"1967","journal-title":"Blood."},{"key":"2020012418391154500_B35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","article-title":"Gp130 and the interleukin-6 family of cytokines.","volume":"15","author":"Taga","year":"1997","journal-title":"Annu Rev Immunol."},{"key":"2020012418391154500_B36","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1002\/stem.5530140707","article-title":"The role of recombinant interleukin-11 in megakaryocytopoiesis.","volume":"14 (suppl 1)","author":"Turner","year":"1996","journal-title":"Stem Cells."},{"key":"2020012418391154500_B37","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1002\/j.1460-2075.1994.tb06802.x","article-title":"Cloning of a murine IL-11 receptor alpha chain: requirements for gp130 high affinity binding and signal transduction.","volume":"13","author":"Hilton","year":"1994","journal-title":"EMBO J."},{"key":"2020012418391154500_B38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/stem.150119","article-title":"Expression of murine interleukin-11 and its receptor alpha-chain in adult and embryonic tissues.","volume":"15","author":"Davidson","year":"1997","journal-title":"Stem Cells."},{"key":"2020012418391154500_B39","doi-asserted-by":"crossref","first-page":"20424","DOI":"10.1016\/S0021-9258(18)54940-1","article-title":"Interleukin-11 regulates the hepatic expression of the same plasma protein genes as interleukin-6.","volume":"266","author":"Baumann","year":"1991","journal-title":"J Biol Chem."},{"key":"2020012418391154500_B40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.cb.06.110190.001245","article-title":"Cell biology of von Willebrand factor.","volume":"6","author":"Wagner","year":"1990","journal-title":"Annu Rev Cell Biol."},{"key":"2020012418391154500_B41","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.4049\/jimmunol.164.7.3837","article-title":"IL-11 activates human endothelial cells to resist immune-mediated injury.","volume":"164","author":"Mahboubi","year":"2000","journal-title":"J Immunol."},{"key":"2020012418391154500_B42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1172\/JCI112560","article-title":"Transplantation of normal bone marrow into a pig with severe von Willebrand disease.","volume":"78","author":"Bowie","year":"1986","journal-title":"J Clin Invest."},{"key":"2020012418391154500_B43","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1055\/s-0037-1615397","article-title":"The effects of mpl-ligand, interleukin-6 and interleukin-11 on megakaryocyte and platelet alpha granule proteins.","volume":"80","author":"Philipp","year":"1998","journal-title":"Thromb Haemost."},{"key":"2020012418391154500_B44","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood."},{"key":"2020012418391154500_B45","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V95.5.1703.005k20_1703_1708","article-title":"Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice.","volume":"95","author":"Schwarz","year":"2000","journal-title":"Blood."},{"key":"2020012418391154500_B46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.cellbio.14.1.399","article-title":"Control of translation initiation in animals.","volume":"14","author":"Gray","year":"1998","journal-title":"Annu Rev Cell Dev Biol."},{"key":"2020012418391154500_B47","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood.V95.11.3280","article-title":"Translational pathophysiology: a novel mechanism of human disease.","volume":"95","author":"Cazzola","year":"2000","journal-title":"Blood."},{"key":"2020012418391154500_B48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/cimm.1994.1042","article-title":"Interleukin-6 regulates expression of the Syndecan-1 proteoglycan on B lymphoid cells.","volume":"153","author":"Sneed","year":"1994","journal-title":"Cell Immunol."},{"key":"2020012418391154500_B49","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.4049\/jimmunol.155.3.1489","article-title":"Intercellular adhesion molecule-1 gene expression by glial cells: differential mechanisms of inhibition by IL-10 and IL-6.","volume":"155","author":"Shrikant","year":"1995","journal-title":"J Immunol."},{"key":"2020012418391154500_B50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","article-title":"Patterns of development of tachyphylaxis in patients with hemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).","volume":"82","author":"Mannucci","year":"1992","journal-title":"Br J Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/2\/465\/1590953\/465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/97\/2\/465\/1590953\/465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T20:10:29Z","timestamp":1682280629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/97\/2\/465\/52893\/Interleukin-11-significantly-increases-plasma-von"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,15]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v97.2.465","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,1,15]]}}}